COLUMBIA, S.C., Oct. 31, 2013 /PRNewswire/ -- BDI Pharma, Inc. today announced record sales revenues for Q3 2013, representing a 39% increase compared to the same time period in 2012. This continues the upward trend from the second quarter driving overall growth for the year to over 38%.
"While we continue to evolve the concept of specialty distribution, it is important that we maintain a strong focus on our core competencies," states Richard J. Gaton, Co-President of BDI Pharma. "One of our top priorities over the past six months has been to increase our level of sophistication as a company. From this, we have seen an immediate impact on our revenues, having the most successful financial quarter in BDI Pharma's nearly two decades of existence."
BDI is confident that their focus on core competency enhancements and strategic expansion into alternative distribution will continue this upward trend. "It is encouraging to experience this type of success while simultaneously solving supply chain issues for our manufacturing partners," adds Rick Schindewolf, CFO, BDI Pharma.
About BDI Pharma, Inc.
BDI Pharma has continuously refined the concept of niche distribution, providing solutions beyond the traditional wholesaler model since 1995. We operate as an extension of our partners' sales force, create demand, and move market share with each transaction. In this regard, we maintain a highly selective process when entering into a strategic partnership. Our approach of serving the manufacturers as well as the customers over nearly two decades has proven successful in varied market conditions. This is further supplemented through innovative supply solutions, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, BDI Pharma's home web page www.bdipharma.com (also www.ivig.com) has become an industry-renowned point of reference. Proprietary programs covering comprehensive reimbursement services - www.bdiaccess.com and 855-BDI-CARE; and product consignment - www.bdivantageplus.com; are just a few of the solutions tailored to the needs of the healthcare community.
BDI Pharma's product portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, coagulation factors, high-titer or "hyper" immune globulins, and other specialty injectables. BDI Pharma is recognized as an "ADR," or Authorized Distributor of Record, for all of the manufacturers it represents.
Contact: Brad Davis
Read more news from BDI Pharma.
|SOURCE BDI Pharma, Inc.|
Copyright©2012 PR Newswire.
All rights reserved